![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 11
Zeitschriftenartikel
Fischer, Luca 
ORCID: https://orcid.org/0000-0003-2444-416X; Jiang, Linmiao ORCID: https://orcid.org/0000-0002-9009-4236; Dürig, Jan ORCID: https://orcid.org/0000-0002-7672-3905; Schmidt, Christian; Stilgenbauer, Stephan ORCID: https://orcid.org/0000-0002-6830-9296; Bouabdallah, Krimo; Solal-Celigny, Philippe; Scholz, Christian W.; Feugier, Pierre; Wit, Maike de; Trappe, Ralf Ulrich; Hallek, Michael; Graeven, Ullrich ORCID: https://orcid.org/0000-0001-6082-7710; Hänel, Mathias; Hoffmann, Martin; Delwail, Vincent; Macro, Margaret; Greiner, Jochen ORCID: https://orcid.org/0000-0003-1256-173X; Giagounidis, Aristoteles A. N.; Dargel, Beate; Durot, Eric ORCID: https://orcid.org/0000-0003-3463-0089; Foussard, Charles; Silkenstedt, Elisabeth; Weigert, Oliver ORCID: https://orcid.org/0000-0002-0987-7373; Pott, Christiane ORCID: https://orcid.org/0009-0005-9260-8340; Klapper, Wolfram; Hiddemann, Wolfgang; Unterhalt, Michael; Hoster, Eva ORCID: https://orcid.org/0000-0002-0749-1389; Ribrag, Vincent und Dreyling, Martin
(2024):
The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma—a randomized, open-label phase III trial of the European mantle cell lymphoma network.
In: Leukemia, Bd. 38: S. 1307-1314
[PDF, 1MB]
ORCID: https://orcid.org/0000-0003-2444-416X; Jiang, Linmiao ORCID: https://orcid.org/0000-0002-9009-4236; Dürig, Jan ORCID: https://orcid.org/0000-0002-7672-3905; Schmidt, Christian; Stilgenbauer, Stephan ORCID: https://orcid.org/0000-0002-6830-9296; Bouabdallah, Krimo; Solal-Celigny, Philippe; Scholz, Christian W.; Feugier, Pierre; Wit, Maike de; Trappe, Ralf Ulrich; Hallek, Michael; Graeven, Ullrich ORCID: https://orcid.org/0000-0001-6082-7710; Hänel, Mathias; Hoffmann, Martin; Delwail, Vincent; Macro, Margaret; Greiner, Jochen ORCID: https://orcid.org/0000-0003-1256-173X; Giagounidis, Aristoteles A. N.; Dargel, Beate; Durot, Eric ORCID: https://orcid.org/0000-0003-3463-0089; Foussard, Charles; Silkenstedt, Elisabeth; Weigert, Oliver ORCID: https://orcid.org/0000-0002-0987-7373; Pott, Christiane ORCID: https://orcid.org/0009-0005-9260-8340; Klapper, Wolfram; Hiddemann, Wolfgang; Unterhalt, Michael; Hoster, Eva ORCID: https://orcid.org/0000-0002-0749-1389; Ribrag, Vincent und Dreyling, Martin
(2024):
The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma—a randomized, open-label phase III trial of the European mantle cell lymphoma network.
In: Leukemia, Bd. 38: S. 1307-1314
[PDF, 1MB]
Fischer, Luca ORCID: https://orcid.org/0000-0003-2444-416X; Jiang, Linmiao ORCID: https://orcid.org/0000-0002-9009-4236; Bittenbring, Joerg Thomas; Huebel, Kai; Schmidt, Christian; Duell, Johannes; Metzner, Bernd; Krauter, Juergen; Glass, Bertram; Huettmann, Andreas; Schaefer-Eckart, Kerstin; Silkenstedt, Elisabeth; Klapper, Wolfram; Hiddemann, Wolfgang; Unterhalt, Michael; Dreyling, Martin und Hoster, Eva ORCID: https://orcid.org/0000-0002-0749-1389
(2023):
The addition of rituximab to chemotherapy improves overall survival in mantle cell lymphoma—a pooled trials analysis.
In: Annals of Hematology, Bd. 102: S. 2791-2801
[PDF, 1MB]
ORCID: https://orcid.org/0000-0003-2444-416X; Jiang, Linmiao ORCID: https://orcid.org/0000-0002-9009-4236; Bittenbring, Joerg Thomas; Huebel, Kai; Schmidt, Christian; Duell, Johannes; Metzner, Bernd; Krauter, Juergen; Glass, Bertram; Huettmann, Andreas; Schaefer-Eckart, Kerstin; Silkenstedt, Elisabeth; Klapper, Wolfram; Hiddemann, Wolfgang; Unterhalt, Michael; Dreyling, Martin und Hoster, Eva ORCID: https://orcid.org/0000-0002-0749-1389
(2023):
The addition of rituximab to chemotherapy improves overall survival in mantle cell lymphoma—a pooled trials analysis.
In: Annals of Hematology, Bd. 102: S. 2791-2801
[PDF, 1MB]
Silkenstedt, Elisabeth ORCID: https://orcid.org/0000-0003-2676-0860 und Dreyling, Martin ORCID: https://orcid.org/0000-0002-0358-5249
(2023):
Mantle cell lymphoma—Update on molecular biology, prognostication and treatment approaches.
In: Hematological Oncology, Bd. 41, Nr. S1: S. 36-42
[PDF, 452kB]
ORCID: https://orcid.org/0000-0003-2676-0860 und Dreyling, Martin ORCID: https://orcid.org/0000-0002-0358-5249
(2023):
Mantle cell lymphoma—Update on molecular biology, prognostication and treatment approaches.
In: Hematological Oncology, Bd. 41, Nr. S1: S. 36-42
[PDF, 452kB]
Moosburner, Marie; Alibegovic, Lamija; Hasselmann, Korbinian ORCID: https://orcid.org/0009-0000-5907-6841; Gaiderov, Anton; Hildebrand, Johannes; Philippou‐Massier, Julia; Blum, Helmut; Fischer, Luca ORCID: https://orcid.org/0000-0003-2444-416X; Dreyling, Martin ORCID: https://orcid.org/0000-0002-0358-5249 und Silkenstedt, Elisabeth ORCID: https://orcid.org/0000-0003-2676-0860
(2023):
Combined treatment with crizotinib and temsirolimus is an effective strategy in mantle cell lymphoma and can overcome acquired resistance to temsirolimus.
In: Hematological Oncology, Bd. 41, Nr. 5: S. 858-868
[PDF, 1MB]
ORCID: https://orcid.org/0009-0000-5907-6841; Gaiderov, Anton; Hildebrand, Johannes; Philippou‐Massier, Julia; Blum, Helmut; Fischer, Luca ORCID: https://orcid.org/0000-0003-2444-416X; Dreyling, Martin ORCID: https://orcid.org/0000-0002-0358-5249 und Silkenstedt, Elisabeth ORCID: https://orcid.org/0000-0003-2676-0860
(2023):
Combined treatment with crizotinib and temsirolimus is an effective strategy in mantle cell lymphoma and can overcome acquired resistance to temsirolimus.
In: Hematological Oncology, Bd. 41, Nr. 5: S. 858-868
[PDF, 1MB]
Mentz, Michael; Keay, William ORCID: https://orcid.org/0000-0002-8794-7322; Strobl, Carolin Dorothea ORCID: https://orcid.org/0000-0003-2257-6281; Antoniolli, Martina ORCID: https://orcid.org/0000-0003-2720-9886; Adolph, Louisa; Heide, Michael; Lechner, Axel; Haebe, Sarah; Osterode, Elisa ORCID: https://orcid.org/0000-0003-4359-2096; Kridel, Robert ORCID: https://orcid.org/0000-0003-0287-7124; Ziegenhain, Christoph ORCID: https://orcid.org/0000-0003-2208-4877; Wange, Lucas Esteban ORCID: https://orcid.org/0000-0002-3275-9156; Hildebrand, Johannes Adrian ORCID: https://orcid.org/0000-0002-5451-8038; Shree, Tanaya ORCID: https://orcid.org/0000-0003-0694-3512; Silkenstedt, Elisabeth; Staiger, Annette M. ORCID: https://orcid.org/0000-0002-5896-3200; Ott, German; Horn, Heike; Szczepanowski, Monika; Richter, Julia ORCID: https://orcid.org/0000-0002-9543-4084; Levy, Ronald; Rosenwald, Andreas; Enard, Wolfgang; Zimber-Strobl, Ursula ORCID: https://orcid.org/0000-0002-9765-5251; Bergwelt-Baildon, Michael von; Hiddemann, Wolfgang; Klapper, Wolfram ORCID: https://orcid.org/0000-0001-7208-4117; Schmidt-Supprian, Marc; Rudelius, Martina; Bararia, Deepak; Passerini, Verena und Weigert, Oliver ORCID: https://orcid.org/0000-0002-0987-7373
(2022):
PARP14 is a novel target in STAT6 mutant follicular lymphoma.
In: Leukemia, Bd. 36, Nr. 9: S. 2281-2292
[PDF, 3MB]
ORCID: https://orcid.org/0000-0002-8794-7322; Strobl, Carolin Dorothea ORCID: https://orcid.org/0000-0003-2257-6281; Antoniolli, Martina ORCID: https://orcid.org/0000-0003-2720-9886; Adolph, Louisa; Heide, Michael; Lechner, Axel; Haebe, Sarah; Osterode, Elisa ORCID: https://orcid.org/0000-0003-4359-2096; Kridel, Robert ORCID: https://orcid.org/0000-0003-0287-7124; Ziegenhain, Christoph ORCID: https://orcid.org/0000-0003-2208-4877; Wange, Lucas Esteban ORCID: https://orcid.org/0000-0002-3275-9156; Hildebrand, Johannes Adrian ORCID: https://orcid.org/0000-0002-5451-8038; Shree, Tanaya ORCID: https://orcid.org/0000-0003-0694-3512; Silkenstedt, Elisabeth; Staiger, Annette M. ORCID: https://orcid.org/0000-0002-5896-3200; Ott, German; Horn, Heike; Szczepanowski, Monika; Richter, Julia ORCID: https://orcid.org/0000-0002-9543-4084; Levy, Ronald; Rosenwald, Andreas; Enard, Wolfgang; Zimber-Strobl, Ursula ORCID: https://orcid.org/0000-0002-9765-5251; Bergwelt-Baildon, Michael von; Hiddemann, Wolfgang; Klapper, Wolfram ORCID: https://orcid.org/0000-0001-7208-4117; Schmidt-Supprian, Marc; Rudelius, Martina; Bararia, Deepak; Passerini, Verena und Weigert, Oliver ORCID: https://orcid.org/0000-0002-0987-7373
(2022):
PARP14 is a novel target in STAT6 mutant follicular lymphoma.
In: Leukemia, Bd. 36, Nr. 9: S. 2281-2292
[PDF, 3MB]
Silkenstedt, Elisabeth und Dreyling, Martin
(2022):
Aggressive Lymphome (DLBCL, MCL) – was ist neu?
In: Deutsche Medizinische Wochenschrift, Bd. 147, Nr. 22: S. 1449-1455
Silkenstedt, Elisabeth und Dreyling, Martin
(2021):
Mantle cell lymphoma-Advances in molecular biology, prognostication and treatment approaches.
In: Hematological Oncology, Bd. 39: S. 31-38
Silkenstedt, Elisabeth; Linton, Kim und Dreyling, Martin
(2021):
Mantle cell lymphoma - advances in molecular biology, prognostication and treatment approaches.
In: British Journal of Haematology, Bd. 195, Nr. 2: S. 162-173
Lopez-Guerra, Monica; Xargay-Torrent, Silvia; Fuentes, Patricia; Roldan, Jocabed; Gonzalez-Farre, Blanca; Rosich, Laia; Silkenstedt, Elisabeth; Garcia-Leon, Maria J.; Lee-Verges, Eriong; Gimenez, Neus; Giro, Ariadna; Aymerich, Marta; Villamor, Neus; Delgado, Julio; Lopez-Guillermo, Armando; Puente, Xose S.; Campo, Elias; Toribio, Maria L. und Colomer, Dolors
(2020):
Specific NOTCH1 antibody targets DLL4-induced proliferation, migration, and angiogenesis in NOTCH1-mutated CLL cells.
In: Oncogene, Bd. 39, Nr. 6: S. 1185-1197
Silkenstedt, Elisabeth; Arenas, Fabian; Colom-Sanmarti, Berta; Xargay-Torrent, Silvia; Higashi, Morihiro; Giro, Ariadna; Rodriguez, Vanina; Fuentes, Patricia; Aulitzky, Walter E.; van der Kuip, Heiko; Bea, Silvia; Toribio, Maria L.; Campo, Elias; Lopez-Guerra, Monica und Colomer, Dolors
(2019):
Notch1 signaling in NOTCH1-mutated mantle cell lymphoma depends on Delta-Like ligand 4 and is a potential target for specific antibody therapy.
In: Journal of Experimental & Clinical Cancer Research, Bd. 38, Nr. 1, 446
Heine, Simon; Kleih, Markus; Gimenez, Neus; Böpple, Kathrin; Ott, German; Colomer, Dolors; Aulitzky, Walter E.; Kuip, Heiko van der und Silkenstedt, Elisabeth
(2018):
Cyclin D1-CDK4 activity drives sensitivity to bortezomib in mantle cell lymphoma by blocking autophagy-mediated proteolysis of NOXA.
In: Journal of Hematology & Oncology
11:112
[PDF, 2MB]